CL2014002406A1 - Metodo para el tratamiento de la depresion refractaria o resistente al taratamiento que comprende administrar esketamina por via intravenosa o intranasal sola o en combinacion con uno o mas antidepresivos; composicion farmaceutica; y su uso en el tratamiento de la depresion refractaria o resistente al tratamiento. - Google Patents

Metodo para el tratamiento de la depresion refractaria o resistente al taratamiento que comprende administrar esketamina por via intravenosa o intranasal sola o en combinacion con uno o mas antidepresivos; composicion farmaceutica; y su uso en el tratamiento de la depresion refractaria o resistente al tratamiento.

Info

Publication number
CL2014002406A1
CL2014002406A1 CL2014002406A CL2014002406A CL2014002406A1 CL 2014002406 A1 CL2014002406 A1 CL 2014002406A1 CL 2014002406 A CL2014002406 A CL 2014002406A CL 2014002406 A CL2014002406 A CL 2014002406A CL 2014002406 A1 CL2014002406 A1 CL 2014002406A1
Authority
CL
Chile
Prior art keywords
treatment
refractory
depression
resistant
antidepressants
Prior art date
Application number
CL2014002406A
Other languages
English (en)
Inventor
Jaskaran Singh
Lodewijik Ivo Caers
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CL2014002406A1 publication Critical patent/CL2014002406A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
CL2014002406A 2012-03-12 2014-09-11 Metodo para el tratamiento de la depresion refractaria o resistente al taratamiento que comprende administrar esketamina por via intravenosa o intranasal sola o en combinacion con uno o mas antidepresivos; composicion farmaceutica; y su uso en el tratamiento de la depresion refractaria o resistente al tratamiento. CL2014002406A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261609641P 2012-03-12 2012-03-12
US201261610058P 2012-03-13 2012-03-13

Publications (1)

Publication Number Publication Date
CL2014002406A1 true CL2014002406A1 (es) 2015-01-09

Family

ID=47913632

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014002406A CL2014002406A1 (es) 2012-03-12 2014-09-11 Metodo para el tratamiento de la depresion refractaria o resistente al taratamiento que comprende administrar esketamina por via intravenosa o intranasal sola o en combinacion con uno o mas antidepresivos; composicion farmaceutica; y su uso en el tratamiento de la depresion refractaria o resistente al tratamiento.

Country Status (14)

Country Link
US (2) US20130236573A1 (es)
KR (1) KR20140136982A (es)
CN (1) CN104519878A (es)
CL (1) CL2014002406A1 (es)
CO (1) CO7071129A2 (es)
CR (1) CR20140410A (es)
GT (1) GT201400191A (es)
HK (1) HK1209323A1 (es)
MX (1) MX2014010939A (es)
NI (1) NI201400104A (es)
PE (1) PE20141906A1 (es)
PH (1) PH12014501997A1 (es)
SG (1) SG11201405530SA (es)
WO (1) WO2013138322A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
US10583138B2 (en) 2012-07-12 2020-03-10 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
SG11201507347QA (en) 2013-03-15 2015-10-29 Janssen Pharmaceutica Nv Pharmaceutical composition of s-ketamine hydrochloride
DK2983787T3 (da) 2013-04-12 2020-01-06 Icahn School Med Mount Sinai Fremgangsmåde til behandling af posttraumatisk stresssygdom
EP3964203A1 (en) 2013-09-13 2022-03-09 National University Corporation Chiba University Application of r-ketamine and salt thereof as pharmaceuticals
ES2726223T3 (es) * 2014-01-14 2019-10-02 Childrens Hospital Med Ct Composiciones que comprenden ketamina para el tratamiento de un trastorno del espectro autista
KR20170013890A (ko) * 2014-05-06 2017-02-07 노쓰웨스턴유니버시티 Nmdar 조절 화합물의 조합물
MX2017001908A (es) * 2014-08-13 2017-08-08 Janssen Pharmaceutica Nv Metodo para el tratamiento de la depresion.
JP2017528483A (ja) * 2014-09-15 2017-09-28 ヤンセン ファーマシューティカ エヌ．ベー． Ｖａｌ６６Ｍｅｔ（ＳＮＰ ｒｓ６２６５）遺伝子型特異的投薬レジメン及びうつ病の治療のための方法
CA2970065A1 (en) 2014-12-08 2016-06-16 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
US20180015054A1 (en) * 2014-12-31 2018-01-18 Icahn School Of Medicine At Mount Sinai Method of Maintaining the Anti-Depressant Effect of Ketamine With Lithium
US9844551B2 (en) 2015-01-14 2017-12-19 Children's Hospital Medical Center Compositions and methods for treatment of fragile X syndrome
WO2016172672A1 (en) * 2015-04-24 2016-10-27 Icahn School Of Medicine At Mount Sinai Method for treating suicidal ideation
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
US20160338977A1 (en) * 2015-05-20 2016-11-24 Janssen Pharmaceutica Nv Methods and kits for treating depression
KR102299359B1 (ko) 2015-06-27 2021-09-07 쉐녹스 파마슈티컬스, 엘엘씨 케타민 경피 전달 시스템
CN106562952B (zh) * 2015-10-09 2020-06-09 江阴安博生物医药有限公司 氯胺酮在治疗重性抑郁障碍中的应用
US11110070B2 (en) 2015-11-17 2021-09-07 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms
JPWO2018079693A1 (ja) * 2016-10-27 2019-10-31 国立大学法人千葉大学 （ｓ）−ノルケタミンおよびその塩の医薬品としての応用
US11723883B2 (en) 2017-06-23 2023-08-15 Ketabon Gmbh Hydroxynorketamine for the use in the treatment of depression
US11622948B2 (en) 2017-11-09 2023-04-11 The Trustees Of Columbia University In The City Of New York Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders
CN107823195A (zh) * 2017-11-24 2018-03-23 无锡市精神卫生中心 R‑氯胺酮在抑郁症急性期治疗中的应用
MX2020006650A (es) * 2017-12-22 2020-11-06 Janssen Pharmaceuticals Inc Esketamina para el tratamiento de la depresión.
EP3505157B1 (en) * 2017-12-29 2021-12-08 Celon Pharma S.A. Dry powder ketamine composition for pulmonary administration in treatment-resistant depression
CN112533595A (zh) 2018-05-04 2021-03-19 感知神经科学公司 治疗物质滥用的方法
US20200000748A1 (en) * 2018-06-27 2020-01-02 Clexio Biosciences Ltd. Method of treating major depressive disorder
WO2020027344A1 (en) * 2018-08-03 2020-02-06 Takeda Pharmaceutical Company Limited Ch24h inhibitors for mdd use
EP3628313A1 (en) 2018-09-28 2020-04-01 Celon Pharma S.A. Ketamine composition for use in a method of treatment of depression by pulmonary administration
EP3860579A1 (en) 2018-10-05 2021-08-11 Clexio Biosciences Ltd. Dosage regime of esketamine for treating major depressive disorder
US20220117975A1 (en) * 2019-02-17 2022-04-21 Neurawell Therapeutics Compositions and methods for treatment of depression and other disorders
WO2020178653A1 (en) * 2019-03-05 2020-09-10 Janssen Pharmaceuticals, Inc. Esketamine for the treatment of depression
JP2022542746A (ja) 2019-05-31 2022-10-07 セロン ファーマ エス．アー． 医薬組成物の電子的に監督された投与
JP2022541872A (ja) 2019-05-31 2022-09-28 セロン ファーマ エス．アー． 医薬組成物の電子的に監督された非経口投与のための吸入器
CN114286674A (zh) * 2019-08-28 2022-04-05 杨森制药公司 用于治疗患有包括自杀倾向在内的重性抑郁障碍的患者的艾司氯胺酮
WO2021048638A1 (en) * 2019-09-13 2021-03-18 Janssen Pharmaceuticals, Inc. Intranasal administration of esketamine
CN115768519A (zh) * 2020-05-28 2023-03-07 詹森药业有限公司 治疗抑郁症的方法
WO2023162987A1 (ja) * 2022-02-22 2023-08-31 国立大学法人京都大学 うつ病および／またはうつ状態の治療および／または予防用医薬

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6176242B1 (en) * 1999-04-30 2001-01-23 Medtronic Inc Method of treating manic depression by brain infusion
EP1103256A1 (de) * 1999-11-26 2001-05-30 Claudius Dr. med. Böck Verwendung von Ketamin zur Behandlung von neuroendokriner Immundysfunktion und algogenem Psychosyndrom
WO2004010932A2 (en) * 2002-07-30 2004-02-05 Peter Migaly Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
US7273889B2 (en) * 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
JP2009530385A (ja) * 2006-03-22 2009-08-27 マウント シナイ スクール オブ メディシン うつ病の治療のためのケタミンの鼻内投与
MX2008014843A (es) * 2006-05-22 2008-12-05 Vanda Pharmaceuticals Inc Tratamiento de trastornos depresivos.
DE102007009888A1 (de) * 2007-02-28 2008-09-04 Hermann, Holger Lars, Dr. Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen
US20110038807A1 (en) * 2009-08-14 2011-02-17 Demitri Papolos Compositions and methods for treating bipolar disorder
AR081931A1 (es) * 2010-06-15 2012-10-31 Gruenenthal Gmbh Combinacion farmaceutica

Also Published As

Publication number Publication date
KR20140136982A (ko) 2014-12-01
MX2014010939A (es) 2014-11-13
NI201400104A (es) 2016-11-30
PE20141906A1 (es) 2014-12-05
CR20140410A (es) 2014-11-17
CO7071129A2 (es) 2014-09-30
PH12014501997A1 (en) 2014-11-24
HK1209323A1 (en) 2016-04-01
US20130236573A1 (en) 2013-09-12
CN104519878A (zh) 2015-04-15
WO2013138322A1 (en) 2013-09-19
US20140093592A1 (en) 2014-04-03
SG11201405530SA (en) 2014-11-27
GT201400191A (es) 2017-07-03

Similar Documents

Publication Publication Date Title
CL2014002406A1 (es) Metodo para el tratamiento de la depresion refractaria o resistente al taratamiento que comprende administrar esketamina por via intravenosa o intranasal sola o en combinacion con uno o mas antidepresivos; composicion farmaceutica; y su uso en el tratamiento de la depresion refractaria o resistente al tratamiento.
CL2013001410A1 (es) Variante polipeptidica de fgf21; multimero que la comprende; composicion farmaceutica que la comprende; y su uso para tratar uno o mas trastornos asociados a fgf21.
CL2012002606A1 (es) Composicion farmaceutica que comprende (-)-carvona, (+)-carvona, trans-geraniol y al menos un componente elegido de aceites esenciales para uso en el tratamiento y prevencion de enfermedades virales.
CL2014001994A1 (es) Polipeptido mimético de apelina sintéticos para el tratamiento e insuficiencia cardiaca; composicion farmacéutica que comprende dicho polipeptido.
CL2013003019A1 (es) Compuestos derivados de benzotiazol; composicion farmaceutica que los comprende; y su uso en el tratamiento del vih.
CL2015001207A1 (es) Composición para prevenir o tratar diabetes, diabesidad o complicaciones diabéticas, que comprende un análogo de oxintomodulina; y uso de la composición.
BR112015003397A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente.
BR112015003332A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
CL2015002472A1 (es) Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4.
BR112015003398A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
CL2015002860A1 (es) Antagonistas de la alfa-v-beta-6 integrina
CL2014002873A1 (es) Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
CL2013002125A1 (es) Compuestos derivados de imidazo[5,1-f][1,2,4]triazinas; composicion farmaceutica; y uso en el tratamiento del deterioro cognitivo asociado con esquizofrenia.
CL2012000620A1 (es) Formulaciones farmaceuticas de un anticuerpo anti cd-20; uso de la formulacion para tratar enfermedad o trastorno que pueda corregirse mediante tratamiento con anticuerpo anti-cd20.
AR089993A1 (es) Macrociclos peptidomimeticos
AR090465A1 (es) Formas solidas de un profarmaco de nucleotidos de tiofosforamidato
BR112014026740A2 (pt) anticorpo, composição, métodos para tratar um mamífero e para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo
CL2014002326A1 (es) Combinacion que comprende benzodioxanos y uno o mas agentes activos y su uso en el tratamiento de enfermedades tales como ateroesclerosis e infarto al miocardio.
CL2014002919A1 (es) Compuestos derivados de 1h-indol-4-il-metil-(heterociclo benzofusionado); composicion y combinacion farmaceutica; y uso en el tratamiento de un trastorno mediado por la activacion del complemento o la ruta alternativa del mismo.
EA201200484A1 (ru) Фармацевтическая композиция с действующими веществами - метформином и ситаглиптином или вилдаглиптином
AR125920A2 (es) Composiciones que comprenden vortioxetina y donepezil
CL2015000976A1 (es) Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociados.
BR112014021068A2 (pt) Inibidor de uma interação entre fosfatidilserina e um receptor tim, composição farmacêutica e uso de um inibidor
CL2015001202A1 (es) Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer.
CL2014003325A1 (es) Compuestos derivados de difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos, inhibidores de bace 1; composicion farmaceutica; y su uso en el tratamiento de enfermedades con niveles elevados de beta-amiloide, tal como la enfermedad de alzheimer